Valuation: CSPC Pharmaceutical Group Ltd.

Market Cap 96.15B 12.26B 10.75B 9.96B 9.17B 17.28B 1,181B 17.49B 119B 46.51B 579B 46.03B 45.04B 1,998B P/E 2026 *
11.7x
P/E 2027 * 13.6x
Enterprise Value 85.29B 10.88B 9.53B 8.83B 8.13B 15.33B 1,047B 15.52B 105B 41.25B 513B 40.83B 39.95B 1,772B EV / Sales 2026 *
2.39x
EV / Sales 2027 * 2.35x
Free-Float
67.42%
Yield 2026 *
4.32%
Yield 2027 * 4.38%
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 47 2004-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 66 2012-12-20
Director/Board Member 56 2025-12-18
Change 5-day change 1-year change 3-year change Capi.($)
+3.00%-.--% - - 12.26B
+2.49%+1.98%+54.22%+154.40% 1,048B
+0.72%-1.28%+52.48%+47.25% 603B
+1.07%+4.62%+38.54%+78.17% 452B
+0.12%+1.45%+31.84%+22.49% 327B
+0.23%+3.18%+36.60%+38.63% 283B
+1.59%+1.19%+22.84%+17.96% 259B
-0.35%-2.50%-23.97%-41.40% 219B
+0.57%+3.09%+23.78%+55.97% 198B
-2.20%+0.18%+20.32%+61.56% 162B
Average +0.27%+1.74%+28.52%+48.34% 394.63B
Weighted average by Cap. -0.27%+1.69%+38.12%+73.38%

Financials

2026 *2027 *
Net sales 35.68B 4.55B 3.99B 3.69B 3.4B 6.41B 438B 6.49B 44.1B 17.26B 215B 17.08B 16.71B 741B 35.2B 4.49B 3.93B 3.64B 3.35B 6.33B 432B 6.4B 43.5B 17.02B 212B 16.85B 16.48B 731B
Net income 7.94B 1.01B 887M 822M 757M 1.43B 97.48B 1.44B 9.81B 3.84B 47.77B 3.8B 3.72B 165B 6.92B 882M 773M 716M 659M 1.24B 84.95B 1.26B 8.55B 3.35B 41.63B 3.31B 3.24B 144B
Net Debt -10.86B -1.39B -1.21B -1.12B -1.04B -1.95B -133B -1.98B -13.43B -5.25B -65.38B -5.2B -5.09B -226B -13.44B -1.71B -1.5B -1.39B -1.28B -2.42B -165B -2.44B -16.61B -6.5B -80.89B -6.43B -6.29B -279B
Logo CSPC Pharmaceutical Group Ltd.
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A